Page 124 - Eceptor News Today

A new study aimed to describe the roles of certain specific mutations in SARS-CoV-2 strains, with respect to their ability to conformationally stabilize S-protein structure resulting in enhanced receptor-binding domain ACE2 binding.

A study, published online in the journal mAbs, describes a novel mAb, UT28K, that has promising broadly neutralizing activity against the SARS-CoV-2 virus.

Results from a new mouse model may aid in understanding how depression and prolonged and severe stress increase the risk of cardiovascular disease, according to preliminary research presented at the American Heart Association's Vascular Discovery: From Genes to Medicine Scientific Sessions 2022.

The US Centers for Disease Control and Prevention (CDC) has conducted national-level genomic surveillance to identify and characterize delta-omicron recombinant genomes of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A total of nine genomes with a hybrid delta-omicron spike protein have been identified.

A recent study published in the journal Antiviral Research explored alternative sources of polyclonal antibodies against SARS-CoV-2, which would be more cost-effective, amendable to regulatory approval, and widespread use.

A team of scientists has recently studied the kinetic and thermodynamic characteristics of interaction between human ACE2 and spike receptor-binding domains of different variants of SARS-CoV-2.

Northwestern Medicine investigators have identified a gene that confers resistance to a common prostate cancer treatment, according to a study published in Cancer Research.

Researchers demonstrated that the biosynthetic proteins called αReps addressing the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein could be novel SARS-CoV-2 antivirals

A new study published in the journal EMBO Reports has reported on the shedding of two proteases, namely, ADAM10 and ADAM17, which aids in S protein-dependent molecular events.

In a recent study published in the journal Vaccines, researchers revealed how severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) Omicron evades neutralizing antibodies (nAbs).